121 related articles for article (PubMed ID: 23115948)
1. Intensity and distribution of immunohistochemical expression of galectin-3 in thyroid neoplasms.
Matesa-Anić D; Moslavac S; Matesa N; Cupić H; Kusić Z
Acta Clin Croat; 2012 Jun; 51(2):237-41. PubMed ID: 23115948
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions.
Oestreicher-Kedem Y; Halpern M; Roizman P; Hardy B; Sulkes J; Feinmesser R; Stern Y
Head Neck; 2004 Nov; 26(11):960-6. PubMed ID: 15386597
[TBL] [Abstract][Full Text] [Related]
3. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS
Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
[TBL] [Abstract][Full Text] [Related]
4. Role of pro-angiogenic marker galectin-3 in follicular neoplasms of thyroid.
Manivannan P; Siddaraju N; Jatiya L; Verma SK
Indian J Biochem Biophys; 2012 Oct; 49(5):392-4. PubMed ID: 23259327
[TBL] [Abstract][Full Text] [Related]
5. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.
Mehrotra P; Okpokam A; Bouhaidar R; Johnson SJ; Wilson JA; Davies BR; Lennard TW
Histopathology; 2004 Nov; 45(5):493-500. PubMed ID: 15500653
[TBL] [Abstract][Full Text] [Related]
6. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.
Mataraci EA; Ozgüven BY; Kabukçuoglu F
Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608
[TBL] [Abstract][Full Text] [Related]
7. Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms.
Aron M; Kapila K; Verma K
Indian J Pathol Microbiol; 2006 Jul; 49(3):376-80. PubMed ID: 17001889
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of galectin-3 immunohistochemistry in differential diagnosis between thyroid follicular carcinoma and follicular adenoma.
Jakubiak-Wielganowicz M; Kubiak R; Sygut J; Pomorski L; Kordek R
Pol J Pathol; 2003; 54(2):111-5. PubMed ID: 14575419
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid.
Rossi ED; Raffaelli M; Mule' A; Miraglia A; Lombardi CP; Vecchio FM; Fadda G
Histopathology; 2006 Jun; 48(7):795-800. PubMed ID: 16722927
[TBL] [Abstract][Full Text] [Related]
10. The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor.
Cui W; Lu X; Zheng S; Ma Y; Liu X; Zhang W
Clin Lab; 2012; 58(5-6):419-26. PubMed ID: 22783570
[TBL] [Abstract][Full Text] [Related]
11. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms.
Inohara H; Honjo Y; Yoshii T; Akahani S; Yoshida J; Hattori K; Okamoto S; Sawada T; Raz A; Kubo T
Cancer; 1999 Jun; 85(11):2475-84. PubMed ID: 10357421
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications.
Xu XC; el-Naggar AK; Lotan R
Am J Pathol; 1995 Sep; 147(3):815-22. PubMed ID: 7677193
[TBL] [Abstract][Full Text] [Related]
13. Galectin-3 expression in follicular tumours: an immunohistochemical study of its use as a marker of follicular carcinoma.
Ito Y; Yoshida H; Tomoda C; Miya A; Kobayashi K; Matsuzuka F; Yasuoka H; Kakudo K; Inohara H; Kuma K; Miyauchi A
Pathology; 2005 Aug; 37(4):296-8. PubMed ID: 16194828
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical distinction of follicular thyroid adenomas and follicular carcinomas.
Bryson PC; Shores CG; Hart C; Thorne L; Patel MR; Richey L; Farag A; Zanation AM
Arch Otolaryngol Head Neck Surg; 2008 Jun; 134(6):581-6. PubMed ID: 18559722
[TBL] [Abstract][Full Text] [Related]
15. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294
[TBL] [Abstract][Full Text] [Related]
16. [Low galectin-3 capacity to discriminate thyroid lesions].
De-León-Mazariegos R; Canedo-Patzi M; Pérez-Enríquez B; Candanedo-Gonzalez F; Saqui-Salces M; Gamboa-Domínguez A; Rull-Rodrigo JA
Rev Invest Clin; 2004; 56(5):623-8. PubMed ID: 15776867
[TBL] [Abstract][Full Text] [Related]
17. Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors.
Martins L; Matsuo SE; Ebina KN; Kulcsar MA; Friguglietti CU; Kimura ET
J Clin Endocrinol Metab; 2002 Oct; 87(10):4806-10. PubMed ID: 12364477
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.
de Matos PS; Ferreira AP; de Oliveira Facuri F; Assumpção LV; Metze K; Ward LS
Histopathology; 2005 Oct; 47(4):391-401. PubMed ID: 16178894
[TBL] [Abstract][Full Text] [Related]
19. Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas.
Saggiorato E; Aversa S; Deandreis D; Arecco F; Mussa A; Puligheddu B; Cappia S; Conticello S; Papotti M; Orlandi F
J Endocrinol Invest; 2004 Apr; 27(4):311-7. PubMed ID: 15233548
[TBL] [Abstract][Full Text] [Related]
20. Galectin-3 and CD44v6 as markers for preoperative diagnosis of thyroid cancer by RT-PCR.
Samija I; Mateša N; Lukač J; Kusić Z
Diagn Mol Pathol; 2011 Dec; 20(4):233-41. PubMed ID: 22089351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]